Four DL-8M high-capacity refrigerated centrifuges from Shanghai Luxiangyi have been shipped to Guangdong, meeting the production needs for fibrinogen and prothrombin.

　　May is the season of harvest. Recent news reports that Shanghai Luxiangyi Centrifuge Instrument Co., Ltd. (hereinafter referred to as “Shanghai Luxiangyi”) has loaded four DL-8M high-capacity refrigerated centrifuges onto a logistics truck, which will soon be shipped to a biotechnology company in Guangdong for the production of fibrinogen and prothrombin.

　　Shanghai Luxiangyi staff will Centrifuge Loading onto a logistics truck (Note: All images in this article are provided by Shanghai Luxiangyi.)

　　Prothrombin is a substance that precedes the activation of thrombin and serves as an important coagulation factor in the body. It participates in both the intrinsic and extrinsic pathways of coagulation. When prothrombin is activated into thrombin, it acquires potent coagulant activity and can also activate fibrinogen to convert it into fibrin, thereby forming fibrin polymers that exert the function of blood clotting. It is thus applicable to various bleeding disorders. Fibrinogen itself also possesses coagulant properties and is primarily used for congenital hypofibrinogenemia or fibrinogen deficiency. It can also be employed in cases of severe liver damage, disseminated intravascular coagulation, postpartum hemorrhage, or acquired fibrinogen deficiency caused by surgery, trauma, or internal bleeding.

　　Blood products are critical strategic reserve materials for the nation and essential emergency medications for treating serious diseases. In recent years, driven by factors such as China’s accelerating economic development, an aging population, and ongoing healthcare reforms, the clinical demand for blood products in China has been steadily increasing, and the industry’s scale continues to expand. Data shows that China’s blood products market has now surpassed 40 billion yuan in size. However, compared with mature markets in Europe and the U.S., there remains substantial room for growth. It is projected that the future market capacity of China’s blood products industry could exceed 100 billion yuan.

　　The “14th Five-Year Plan” and the 2035 Vision Outline explicitly state that the country will accelerate the development of the biopharmaceutical industry and strengthen and expand the bioeconomy. The “14th Five-Year Plan for the Pharmaceutical Industry Development” also clearly emphasizes implementing the strategy of building a manufacturing powerhouse, comprehensively promoting the Healthy China initiative, fully upgrading the modernization level of the pharmaceutical industry chain, improving the pharmaceutical supply and guarantee system, and better meeting the diverse and multi-level health needs of the people. With the successive introduction of a series of favorable policies, China’s blood products industry will further benefit from rapid development, and there is substantial potential for domestic substitution as well as overseas exports.

　　Currently, numerous biotechnology companies have entered the blood products market. Against this backdrop, the upstream centrifuge equipment industry is also experiencing new development opportunities. However, given the special nature of blood products and their extremely high safety requirements, centrifuge equipment manufacturers face significant barriers to entry.

　　It is reported that Shanghai Luxiangyi’s DL-8M ultra-large-capacity refrigerated centrifuge in this batch is specially designed for customers with high-volume requirements. It can simultaneously separate 12 × 400ml triple-bag or quadruple-bag samples, as well as 24 × 200ml triple-bag samples. This equipment features an imported high-performance compressor unit and uses the fluorine-free refrigerant R404a, meeting environmental protection standards and delivering excellent cooling performance. It is equipped with an electronic door lock and comes with multiple protective functions, including door cover protection, overspeed protection, overtemperature protection, and imbalance detection. It also boasts an automatic alarm system for fault detection, ensuring safe and reliable operation. Moreover, it comes with a food-grade silicone rubber integral sealing ring that complies with GMP certification. With its large sample-processing capacity, this model is an ideal choice for central blood banks, pharmaceutical companies, bioengineering institutions, and other related fields.

　　DL-8M High-Capacity Refrigerated Centrifuge

　　100026S

　　Behind the successful collaboration between Shanghai Luxiangyi and a certain biotech company in Guangdong, we can see the Guangdong-based biotech company’s recognition and appreciation of our centrifuge brand’s strength.

　　For years, Shanghai Luxiangyi has adhered to the principle of “customer first” and pursued the goal of “continuous innovation for the future.” We remain committed to serving our customers with a corporate spirit characterized by “pragmatism, innovation, dedication, and pursuit of excellence.” Thanks to our reliable product quality and outstanding service, Shanghai Luxiangyi’s centrifuges are now in use at numerous biotechnology companies across China and have earned the trust and favor of our customers!